Baxter raises 2026 outlook as second-quarter sales rise 5% to $2.96 billion
Baxter reported second-quarter 2026 sales of $2.96 billion, up 5%, and U.S. GAAP diluted EPS of $0.26, while adjusted diluted EPS of $0.56 fell 5% from a year earlier. The company raised its full-year 2026 adjusted EPS outlook to $1.95 to $2.15 from $1.85 to $2.05, and the results included a $0.11 per-share benefit from an IEEPA tariff refund. Shareholders also get a $0.01 quarterly dividend, payable October 1, 2026.
Key points
- Q2 2026 sales of $2.96 billion rose 5% on both reported and organic bases; U.S. GAAP net income was $135 million from continuing operations.
- Adjusted diluted EPS was $0.56, down from $0.59 a year earlier, partly offset by a $0.11 per-share IEEPA tariff refund benefit.
- Full-year 2026 adjusted EPS guidance raised to $1.95 to $2.15 from $1.85 to $2.05; reported sales growth guidance raised to 3% to 4% from flat to 1%.
- Board declared a quarterly cash dividend of $0.01 per share, payable October 1, 2026, to holders of record as of August 28, 2026.
The filing
Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 8, 2026, 1:12 AM ET, from the text of the filing and its press-release exhibits only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on July 30, 2026.
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.